deziglipel   Click here for help

GtoPdb Ligand ID: 14614

Synonyms: compound 1086 [WO2017175066] | compound 32 [PMID: 41054342] | MKP-10241 | MKP10241
Compound class: Synthetic organic
Comment: Deziglipel is the INN for a G-protein-coupled receptor 119 (GPR119) agonist, as presented in WHO INN Proposed List 135 (July 2026). It is proposed for the treatment of steatohepatitis and type 2 diabetes in this INN record. It is one of the compounds claimed in patents held by Mankind Pharma that are disigned to target the GPR119/incretin axis as a mechanism to treat metabolic disorders [1]. and deziglipel is a structural match for the declared GPR119 clinical lead MKP10241 [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 0
Rotatable bonds 7
Topological polar surface area 132.97
Molecular weight 530.64
XLogP 2.48
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCC1=CN=C(N=C1)N2CCC(CC2)[C@H](C)OC3=NN4C=C(C5=C(C=C(C=C5)S(=O)(=O)C)F)N=C4S3
Isomeric SMILES C(C)C=1C=NC(=NC1)N2CCC(CC2)[C@H](C)OC3=NN4C(S3)=NC(=C4)C5=C(C=C(C=C5)S(=O)(=O)C)F
InChI InChI=1S/C24H27FN6O3S2/c1-4-16-12-26-22(27-13-16)30-9-7-17(8-10-30)15(2)34-24-29-31-14-21(28-23(31)35-24)19-6-5-18(11-20(19)25)36(3,32)33/h5-6,11-15,17H,4,7-10H2,1-3H3/t15-/m0/s1
InChI Key UUMBXZTUKTTYMG-HNNXBMFYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Patil RI, Gunjal AP, Verma J, Kumar P, Rai AK, Rai H, Kumar A. (2017)
Heterocyclic gpr119 agonist compounds.
Patent number: WO2017175066A1. Assignee: Mankind Pharma Ltd. Priority date: 05/04/2017. Publication date: 12/10/2017.
2. Rai SK, Patil RI, Ali S, Kumar R, Khan MI, Panwar A, Reddy S, Ahsan M, Iyer S, Kumar A. (2025)
Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders.
J Med Chem, 68 (22): 23781-23800. [PMID:41054342]